Remepy, a pioneer in Hybrid Drugs™, today announced that the Phase IIa clinical trial of Hybridopa™, a new Hybrid Drug for Parkinson's disease, met its primary endpoint, delivering statistically ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke, preeclampsia and fetal growth restriction, ...

Remepy, a pioneer in Hybrid Drugstm, today announced that the Phase IIa clinical trial of Hybridopatm, a new Hybrid Drug for Parkinson's disease, met its primary endpoint, delivering statistically ...

Significantly lower TLF rates (2.8% versus 7.8%, p=0.020) with DynamX® compared to Resolute Onyx DES with no new events in bioadaptor arm between 3 and 4 years 88% reduction in Cardiovascular Death (0 ...

Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the ...

Elixir Medical announced four-year results from a study comparing its DynamX coronary bioadaptor system to a leading ...

The answer has less to do with morning people’s discipline than with deep evolutionary history, and a molecular clock ticking ...

The FDA still requires convincing safety and efficacy data on psychedelic agents, including MDMA, before approval. The VA and ...

Envestnet, the leading Adaptive WealthTech company, today announced the latest product enhancements on its Tamarac platform, delivering new capabilities designed to help financial advisors manage ...

A study found that childhood abuse may increase the risk of harmful adult relationships through emotional and behavioral ...

Randomized Phase 2 trial evaluates off-the-shelf invariant natural killer T (iNKT) cell therapy in patients with acute lung ...

You'd think meditating, something that people have been doing for thousands of years, would be fully understood. Yet for ...